54 results about "Malignant cells" patented technology

This disclosure provides novel bispecific antibodies that specifically bind to CD47 and Programmed Death-Ligand 1 (PD-L1). The disclosure further relates to methods of making the bispecific antibodies and nucleic acids encoding the antibodies. The disclosure further relates to therapeutic methods for use of the bispecific antibodies in the treatment of a condition associated with malignant cells expressing CD47 and / or PD-L1.

Methods for treating cancers and precancerous conditions by administering an effective amount of a radiolabeled agent that targets cell surface phosphatidylserine, alone or in combination with other therapies, are provided. The radiolabeled phosphatidylserine targeting agent delivers radiation to cells that externally present phosphatidylserine, such as tumor cells, depleting those cells and neighboring malignant cells to effect overall tumor reduction. Radiation delivered by the radiolabeled phosphatidylserine targeting agent itself increases the cell surface expression of phosphatidylserine, leading to a feed-forward mechanism that drives further accumulation of the phosphatidylserine targeting agent at target lesions to enhance its therapeutic effect.

The invention discloses an early diagnosis marker for B-cell lymphoma, a cross-species screening method based on lamprey and application, and relates to the technical field of molecular diagnosis. In the prior art, tissue biopsy is strong in invasiveness, and a traditional marker is low in early detection rate; in order to solve the problems that a large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large- When the expression quantity of the gene in a sample is greater than or equal to 1.8 times of that of a normal B cell (HMY2. CIR), the lymphoma is judged to be positive, and the minimally invasive early diagnosis efficiency is remarkably improved.

Disclosed herein are prokaryotic homologs of viperin (pVips), and nucleotide and nucleoside analogs produced from pVips. These nucleotide and nucleoside analogs stop nucleotide chain synthesis and provide host cells with resistance to viral infections by targeting actively replicating viral genome. Further, these nucleotide and nucleoside analogs decrease DNA replication in malignant cells. Further disclosed are methods of identifying pVips, and nucleotide and nucleoside analogs produced thereof.

The invention discloses a method for accurately identifying benign and malignant cells based on multi-dimensional characteristics of a single cell transcriptome, and belongs to the technical fields of bioinformatics, tumor molecular biology and cell identification. On the basis of single cell transcriptome sequencing data of tumor tissues and para-carcinoma tissues, three types of information including copy number variation, allele specific copy number variation and tumor-related transcriptional characteristics are synthesized, and final benign and malignant identification is performed on each EpCAM positive epithelial cell through a multi-evidence voting strategy. The method disclosed by the invention has relatively high stability and accuracy in a multi-patient, multi-sample and early tumor scene, particularly improves the recognition capability of early lesion and malignant cells in benign and malignant boundary transition state cells, and provides a reliable technical means for precise diagnosis and individualized treatment of tumors.

A pathological diagnosis support device comprises: an acquisition unit that acquires pathological images including cells as subjects; a determination unit that determines whether malignant cells are included in the pathological images by inputting the pathological images to a machine-trained first classification model; a classification unit that classifies the pathological images by class by inputting the pathological images to a second classification model machine-trained to classify the pathological image into any of a plurality of classes including one or more features suggesting the presence of malignant cells; and an output unit that outputs a classification result and supports a user's decision making.

The application discloses a multi-omics pathological analysis system and method for predicting the risk of colorectal liver metastasis, relates to the technical field of biomedical and cancer diagnosis, and comprises a data acquisition module, a data preprocessing module, a cell analysis module, a score construction module, a model construction and training module and a prediction and evaluation module; the application realizes comprehensive and accurate prediction of the risk of colorectal liver metastasis by integrating multi-omics data, including single-cell data sets, spatial transcriptome data, batch RNA-seq data, clinical data and whole slide image WSIs; the cross-dimension data fusion and analysis not only improve the accuracy and reliability of prediction, but also provide a powerful tool for in-depth exploration of the molecular mechanism of tumor occurrence, development and metastasis, especially in the cell analysis module, identification and analysis of the malignant cell subpopulation LMTMCs triggering liver metastasis can reveal cell subtypes and molecular characteristics closely related to liver metastasis, thereby providing a scientific basis for formulating a personalized treatment plan.

The application belongs to the technical field of medicine, and discloses a method and system for detecting mucinous pancreatic cystic tumor, acquires a pancreatic cyst fluid sample; performs organoid culture on the pancreatic cyst fluid to obtain a mucinous pancreatic cystic tumor organoid; acquires cell morphology data of the mucinous pancreatic cystic tumor organoid; acquires H&E staining data and IHC detection data of the mucinous pancreatic cystic tumor organoid; acquires immunofluorescence detection data of the mucinous pancreatic cystic tumor organoid; performs scRNA-Seq sequencing on the mucinous pancreatic cystic tumor organoid to complete detection of the mucinous pancreatic cystic tumor; and the method can efficiently culture organoids and be used for verifying potential existence of malignant cells in function.

Tumor glycocalyx may be regarded as a glycan “canopy” above the tumor plasma membrane. Disclosed are methods of treating a neoplastic malignant cell cancer wherein the neoplastic malignant cancer cell has a malignant glycocalyx B. Also disclosed are methods of inducing apoptosis of one or more neoplastic malignant cells and methods of increasing a subject's responsiveness to an immunotherapy wherein the neoplastic malignant cancer cell has a malignant glycocalyx B.

This invention provides a combination therapy method to increase the effectiveness of cancer immunotherapy. [Solution] The present invention provides a combination therapy using bosentan and a checkpoint inhibitor that is effective in treating cancer in a target or inhibiting the proliferation of tumor cells, and / or can induce, enhance, or prolong an immune response against tumor cells. The effectiveness of cancer immunotherapy depends on whether T cells can migrate to the tumor, travel to locations adjacent to malignant cells, recognize them, and kill them.

The present invention provides an in-vitro method of reducing the efficiency of transducing malignant cells of the blood system of a subject that are not derived from T cells with lentiviral vector particles without reducing the efficiency of transducing T cells in a sample comprising T cells and said malignant cells. A combination of compositions comprising a first composition and a second composition is also disclosed, wherein said first composition comprises i) transduced T cells of a subject, wherein said transduced T cells express a CAR comprising an antigen binding domain, wherein the antigen binding domain of said CAR binds specifically to a tag of a tagged polypeptide, and ii) non-transduced malignant cells of the blood system of said subject, and wherein said second composition comprises said tagged polypeptide, wherein said tagged polypeptide binds specifically to an antigen expressed on the surface of said malignant cells. Alternatively, the transduced T cells of said first composition may comprise a nucleic acid encoding a CAR and an inducible gene expression system, and said second composition may comprise an induction agent inducing said gene system.

Compounds and methods are disclosed for reducing or preventing metastatic behaviour in VGSC expressing cancer by the effect of at least reducing the persistent part of the voltage gated sodium channel current without eliminating the transient part, thereby inhibiting the metastatic and invasive growth of malignant cells in a cancer patient.

The present disclosure relates to polynucleotides and methods of inhibiting the activities of development-associated pathways, including the Wnt, Hedgehog, and Notch pathways, and the invasive capacity of malignant cells to treat primary or secondary solid tumors.

The invention provides a proliferative cell proportion evaluation method and device, electronic equipment and a storage medium. The method comprises the following steps: acquiring transcriptome data of malignant cells and acquiring immunofluorescence data; acquiring cell classification labels of the malignant cells according to the transcriptome data and the immunofluorescence data of the malignant cells; screening model feature genes according to the transcriptome data of the malignant cells and the cell classification tags of the malignant cells based on a first evaluation model; obtaining target transcriptome data of the malignant cells from the transcriptome data of the malignant cells based on the model characteristic genes; and inputting the target transcriptome data of the malignant cells and the cell classification labels of the malignant cells into a second evaluation model for model training to obtain a trained second evaluation model. Compared with the prior art, the method has the advantages that the proliferative cell proportion is evaluated through the evaluation model, the evaluation result does not need to be manually interpreted, the probability of personal errors is reduced, and the possibility that the evaluation result of the proliferative cell proportion has errors is reduced.

Immunotherapeutic Monoclonal Antibody Complexes or Conjugates (IMAC) comprising readily accessible antibodies designed and approved for clinical use are provided using a one-step method that combines killing of existing cancer cells in parallel with induction of long-lasting anti-cancer vaccination. Methods for their use, alone or in combination with cancer killer cells including intentionally mismatched donor T cells, NK cells concomitantly with additional anti-cancer or immune activating agents, or activation of patient's own immune system for personalized treatment of cancer and elimination of undesirable non-malignant cells are also provided. In addition, treatment method based on IMAC can be applied for in vivo vaccination against cancer using an existing malignant lesion as internal anti-cancer vaccine by engagement of patients antigen presenting cells for induction of long-lasting anti-cancer vaccination in situ against residual or recurrent disease.

Embodiments of the present application disclose a pan-cancer cell recognition model training method, device, equipment and storage medium. The method comprises selecting transcriptome test data of a plurality of preset cancer types according to a preset ratio of normal cells and malignant cells to construct an initial data set; obtaining a preset number of high variable genes in the transcriptome test data of the initial data set as training features to obtain a training set; based on a binary classification label, performing label annotation on the transcriptome test data in the training set to generate a binary classification label system test data set; taking the pre-training weight of a preset base model as an initialization parameter, mounting a binary classification head at the top layer of a transformer layer, and performing parameter fine-tuning on the preset base model based on the binary classification label system test data set to obtain a pan-cancer cell recognition model. The scheme of the embodiments of the present application can realize accurate identification of benign and malignant cells in pan-cancer single-cell transcriptome data.

The present application is related to a method for in situ detection of multiple lung cancer-related markers in live circulating malignant cells, and tumor heterogeneity, including accurately detecting at least one lung cancer-related nucleic acid marker in live lung cancer cells by using a lung cancer-targeted nanoprobe loaded with a plurality of molecular beacons to reflect levels of different markers in the lung cancer cells from a single cell level and a heterogeneous state of a tumor of a specific patient. The nanoprobe is a nanoparticle self-assembled from a high polymer material, an electropositive protein, a functional polypeptide and / or a functional aptamer, and a molecular beacon of a lung cancer-related marker. The nanoprobe can be used to target different phenotype circulating malignant cells in whole blood, detect nucleic acid markers in living cells, and reflect levels of different markers in the malignant cells from a single cell level.

The present disclosure relates to target sequencing of T and B cell receptor gene rearrangements at the DNA level and using this technology to detect and quantify lymphoid malignant T or B cells (minimal residual disease, MRD) during and after therapy.

The present disclosure relates to target sequencing of T and B cell receptor gene rearrangements at the DNA level and using this technology to detect and quantify lymphoid malignant T or B cells (minimal residual disease, MRD) during and after therapy.

The invention relates to the technical field of biology, and discloses a method for discovering a new stomach-tumor target spot and a system establishment method. By integrating single cell second-generation sequencing and third-generation full-length transcriptome technologies and adopting a CopyKat and Infercnv dual algorithm model, the technical limitations that tumor heterogeneity cannot be analyzed by traditional batch sequencing and full-length new transcripts and malignant cells are difficult to accurately identify by conventional single cell sequencing are overcome. The method can systematically and precisely complete the whole process from cell subset analysis, malignant cell identification to brand new membrane protein target discovery, and further improves the reliability and transformation application potential of the discovered target through cross-platform verification and function correlation analysis, and has a wide application prospect. And a more efficient and reliable target spot discovery scheme is provided for gastric cancer targeted therapy and prognosis judgment.

The invention relates to the field of the preparation, identification and selection of biological binding molecules such as antibodies or fragments thereof, and also the use thereof in the context of therapy and prophylaxis of cancers, such as malignant B-cell neoplasia in particular. The binding molecules are capable of selectively binding to B-cell receptors that have a light chain according to SEQ ID NO. 18.

To provide a physical therapy for malignant tumors that is gentle to a living body, inexpensive, and highly effective.SOLUTION: Malignant cells are killed by: forming micropores in the malignant cells by shock wave irradiation, focused high-intensity ultrasound irradiation, photoimmunotherapy, or simultaneous application of microbubbles and ultrasound; and diffusing hydrogen ions, which are present in a large amount in an extracellular fluid of the malignant cells, into the malignant cells by Lorentz force.SELECTED DRAWING: None

Immunotherapeutic Monoclonal Antibody Complexes or Conjugates (IMAC) comprising readily accessible antibodies designed and approved for clinical use are provided using a one-step method that combines killing of existing cancer cells in parallel with induction of long-lasting anti-cancer vaccination. Methods for their use, alone or in combination with cancer killer cells including intentionally mismatched donor T cells, NK cells concomitantly with additional anti-cancer or immune activating agents, or activation of patient's own immune system for personalized treatment of cancer and elimination of undesirable non-malignant cells are also provided. In addition, treatment method based on IMAC can be applied for in vivo vaccination against cancer using an existing malignant lesion as internal anti-cancer vaccine by engagement of patient's antigen presenting cells for induction of long-lasting anti-cancer vaccination in situ against residual or recurrent disease.

A classification assistance device comprises: a division unit that divides an input image, which includes a specimen being a subject that includes a plurality of cells, into a plurality of partial images, each including a plurality of cells as a subject; a patch classification unit that receives input of an image including a plurality of cells as a subject, inputs the partial images to a trained model trained to estimate whether the image includes malignant cells, and classifies whether a partial image includes malignant cells, on the basis of the estimation result of the trained model; a detection unit that detects cells from a partial image, among the plurality of partial images obtained by division by the division unit, that is classified by the patch classification means as including malignant cells; and a cell classification unit that classifies whether the cells detected by the detection unit are malignant cells. According to this classification assistance device, a user, such as a medical worker, can be assisted in making decisions.

This invention provides an antitumor agent that demonstrates efficacy against cancer cells expressing CD123, which has been reported to be overexpressed in malignant cells of a wide range of hematological malignancies. [Solution] Provided are an antibody or its antigen-binding fragment, an immune complex containing the antibody, and a method for using such CD123-binding molecules to diagnose and treat diseases such as B-cell malignancies, (a) an epitope within amino acids 101-346 of the human CD123 / IL3-Rα antigen, and (b) an antibody or its antigen-binding fragment that inhibits IL3-dependent proliferation of antigen-positive TF-1 cells.

The invention relates to the technical field of cellular immunotherapy, in particular to a preparation method of universal CAR-T (Chimeric Antigen Receptor-T) cells for targeting CD19 mediated by umbilical cord blood, and provides a standardized and large-scale preparation scheme aiming at the problems of long preparation period, high cost, large immune risk, limited applicable population and the like of the existing autologous CAR-T cells. The method comprises the steps of umbilical cord blood collection and storage, T cell separation and purification, CD19-targeted CAR gene construction and lentivirus transduction, TCR and HLA-I type molecule knockout through gene editing, CAR-T cell amplification and quality control and the like. The advantages of low immunogenicity and high multiplication capacity of the umbilical cord blood T cells are utilized, an optimized gene modification and culture system is combined, batch production of the CAR-T cells is achieved, the preparation period is shortened, the cost is reduced, adverse reactions such as GVHD and CRS are reduced, the applicable crowd for treatment is expanded, and an efficient and safe new strategy is provided for treatment of malignant B cell diseases.

The disclosure relates to a method for detecting the presence of at least one data point representative of malignant cell proliferation within a histopathological image, said method being implemented within an electronic processing device.Such a process comprises: - a segmentation (S01) of the representative image of the tissue section, yielding a set of tiles of predetermined size, each tile having a position within the representative image of the tissue section; - a determination (S02), for each tile in the set of tiles, of a data point representing the number of malignant cells and a data point representing the total number of cells, these data points being inserted respectively into a first matrix Mp and a second matrix Mt, each element of which is associated with a tile position within the representative image of the tissue section; - a detection (S03) of the presence of malignant cell proliferation within said histopathological image, said detection implementing calculations of data groupings from the first matrix Mp and the second matrix Mt, according to an algorithm for distributing calculations in parallel. Fig. 1.

Provided are androstane and dihydrotestosterone compounds functionalized with carbocyclic groups or heterocyclic groups that may be saturated or unsaturated. The compounds may be used in methods of inhibiting cell growth of malignant cells and / or hyperplastic cells and / or treating individuals having diseases associated with malignant cell growth (e.g., cancer, such as, for example, prostate cancer) and / or hyperplastic cell growth and / or molecular imaging of malignant cells and / or hyperplastic cells and / or inducing degradation of a target protein. Also provided are compositions.

The present invention provides compositions and methods that can be used in methods for treating B-cell malignancies, and which exhibit low toxicity and immunogenicity in humans. [Solution] A chimeric antigen receptor (CAR) for CD19, comprising a specific amino acid sequence, is provided. A method for destroying T cells and malignant B cells expressing the CAR is also provided.

The present disclosure relates to target sequencing of T and B cell receptor gene rearrangements at the DNA level and using this technology to detect and quantify lymphoid malignant T or B cells (minimal residual disease, MRD) during and after therapy.